NCT03316599View on ClinicalTrials.gov

Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 17, 2018

Primary Completion Date

October 10, 2020

Study Completion Date

July 29, 2021

Conditions
Pancreatic Cancer
Interventions
DRUG

Gemcitabine

Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.

DRUG

Nab-paclitaxel

Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells

DRUG

Ficlatuzumab

It is selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

AVEO Pharmaceuticals, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER